Morepen Laboratories net profit up 189%

R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices

Morepen Board proposed dividend after 23 years

Scores highest PAT of Rs. 118 crore in FY25

Morepen to launch new fatty lever drug ‘Resmetirom’

Morepen to add 1,000 medical representatives

The company is targeting a Rs. 1,000 crore finished dosages business within the next five years

Morepen secures Loratadine approval for export to China

This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets

Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care

AstraZeneca Pharma India discontinues manufacturing of Imdur

Morepen launches Empamore for diabetes care with affordable treatment

Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health

Informa Markets in India set to host 17th edition of CPHI & PMEC India Expo

CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof

Dr. Morepen’s diabetes awareness campaign kicks on KBC

This initiative aims to raise awareness about the importance of monitoring blood sugar levels before indulging in sweets

Morpen gets U.S. FDA approval for Fexofinadine

Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever